Skip to main content
Journal cover image

The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.

Publication ,  Journal Article
Lyman, GH; Kuderer, NM
Published in: Crit Rev Oncol Hematol
May 2004

Healthcare costs continue to rise with hospitalization representing the single largest component of direct medical costs associated with cancer care. Neutropenia and its complications including febrile neutropenia remain the major dose-limiting toxicity associated with systemic cancer chemotherapy. Febrile neutropenia often occurs early in the course of chemotherapy and is associated with substantial morbidity, mortality and cost. The colony-stimulating factors (CSFs) have been used effectively in a variety of clinical settings to prevent or treat febrile neutropenia and to assist patients receiving dose-intensive chemotherapy. A meta-analysis of the available randomized controlled trials (RCTs) has confirmed the efficacy of prophylactic CSFs. Economic models based on measures of resource utilization derived from RCTs have provided estimates of expected treatment costs along with febrile neutropenia risk threshold estimates for the cost saving use of the CSFs. Recent studies have demonstrated the potential value of targeting the CSFs toward patients at greatest risk based on accurate and valid predictive models.

Duke Scholars

Published In

Crit Rev Oncol Hematol

DOI

ISSN

1040-8428

Publication Date

May 2004

Volume

50

Issue

2

Start / End Page

129 / 146

Location

Netherlands

Related Subject Headings

  • Survival Rate
  • Quality of Life
  • Oncology & Carcinogenesis
  • Neutropenia
  • Humans
  • Colony-Stimulating Factors
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Kuderer, N. M. (2004). The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol, 50(2), 129–146. https://doi.org/10.1016/j.critrevonc.2004.01.001
Lyman, G. H., and N. M. Kuderer. “The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.Crit Rev Oncol Hematol 50, no. 2 (May 2004): 129–46. https://doi.org/10.1016/j.critrevonc.2004.01.001.
Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004 May;50(2):129–46.
Lyman, G. H., and N. M. Kuderer. “The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.Crit Rev Oncol Hematol, vol. 50, no. 2, May 2004, pp. 129–46. Pubmed, doi:10.1016/j.critrevonc.2004.01.001.
Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004 May;50(2):129–146.
Journal cover image

Published In

Crit Rev Oncol Hematol

DOI

ISSN

1040-8428

Publication Date

May 2004

Volume

50

Issue

2

Start / End Page

129 / 146

Location

Netherlands

Related Subject Headings

  • Survival Rate
  • Quality of Life
  • Oncology & Carcinogenesis
  • Neutropenia
  • Humans
  • Colony-Stimulating Factors
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology